The FDA rejected Applied Therapeutics’ experimental treatment, govorestat, for a rare disease called classic galactosemia, ...

FDA accepts Satsuma Pharmaceuticals' NDA resubmission for STS101 migraine drug. Hovione expands facilities in Ireland and New ...

Idorsia announces 270 potential layoffs, primarily affecting R&D and headquarters support functions. The company is ...

Advanz Pharma's liver treatment Ocaliva lost EU marketing authorization following a court decision. The drug, used for ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Kronos Bio announces 83% workforce reduction and CEO Norbert Bischofberger's departure, with CFO Deborah Knobelman taking ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

Outlook Therapeutics' ONS-5010 (bevacizumab) failed to meet its primary endpoint in a Phase 3 trial against Roche's Lucentis ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...

Novartis is laying off 139 employees in East Hanover, NJ, primarily affecting commercial field sales teams working on Xolair (allergy/asthma) and Tafinlar-Mekinist (cancer) treatments. The cuts, ...